67th Annual Scientific Sessions of the American College of Cardiology 2018

The Word from ACC 2018: ODYSSEY Outcomes

Highlights from ACC.2018: Poster presentations

Real-life experience with PCSK9 inhibition in familial hypercholesterolaemia Familial hypercholesteraemia (FH, inherited high cholesterol) is one of the key groups for whom PCSK9 inhibition is indicated. This prospective registry provided data on 44 patients with genetically verified FH attending a specialist lipid clinic in Norway….

Will the PCSK9 inhibitor trials change guidelines and practice?

Statins are the indisputable backbone of lipid-lowering therapy for prevention of atherosclerotic cardiovascular disease (ASCVD), with add-on ezetimibe proven to provide further benefit in high-risk patients.1 Yet it is clear that even with optimally tolerated statin therapy, a high residual cardiovascular risk persists. In ODYSSEY…

VIDEO: Will the trial evidence now overcome barriers to the use of PCSK9 inhibition?

Will FOURIER and ODYSSEY Outcomes change LDL cholesterol goals in high-risk patients?

VIDEO: Do FOURIER and ODYSSEY Outcomes align with the ESC/EAS Task Force guidance on practical use of PCSK9 inhibition?

Professor Stephen Nicholls (South Australian Health and Medical Research Institute, Adelaide, Australia): How do you interpret the mortality data from ODYSSEY Outcomes?

Professor Stephen Nicholls (South Australian Health and Medical Research Institute, Adelaide, Australia): Would you have expected a greater magnitude of benefit for the primary outcome in ODYSSEY Outcomes?

Professor Raul Santos (University of São Paulo, Brazil): Why was the mortality benefit in ODYSSEY Outcomes only evident after 1 year of follow-up?

Professor Raul Santos (University of São Paulo, Brazil): What are the key take home messages from ODYSSEY Outcomes?

Will ODYSSEY Outcomes change the management of ACS patients?

What is the take home message from ODYSSEY Outcomes regarding the role of LDL cholesterol in CVD prevention?

How do you explain the different mortality results in ODYSSEY Outcomes versus FOURIER?

Does ODYSSEY Outcomes align with FOURIER and the SPIRE cardiovascular outcomes studies?

ODYSSEY Outcomes and FOURIER in context

Highlights from ACC.2018 In the swirling milieu after presentation of the top-line data from ODYSSEY Outcomes, it is important to put the two cardiovascular outcomes studies in context, especially given the all-cause mortality benefit observed in ODYSSEY Outcomes but not in FOURIER.1,2  It is also…

Inclisiran marches on: ORION-4 cardiovascular outcomes study launches

Highlights from ACC.2018 The pace of development of inclisiran, an investigational GalNAc-conjugated RNA interference therapeutic, which reduces synthesis of PCSK9 protein in liver cells, thereby reducing liver cell LDL-receptor turnover, and lowering plasma LDL cholesterol levels is accelerating. Prior to ACC.2018, it was announced that…

Prof John Chapman discusses safety data from the ODYSSEY Outcomes study

Prof Henry Ginsberg discusses the ODYSSEY Outcomes topline data

Prof Greg Schwartz Clinical implications of ODYSSEY Outcomes

Prof Greg Schwartz Key results of ODYSSEY Outcomes